HCWB | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 11%

Liquidity 47%

Performance 7%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.20%

1 Month

-28.72%

3 Months

-26.41%

6 Months

-46.22%

1 Year

-64.78%

2 Year

-79.80%

Key data

Stock price

$0.42

P/E Ratio

-0.45

DAY RANGE

$0.41 - $0.41

EPS

-$1.04

52 WEEK RANGE

$0.31 - $2.52

52 WEEK CHANGE

-$66.83

MARKET CAP

17.437 M

YIELD

N/A

SHARES OUTSTANDING

37.823 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/14/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$397,809

AVERAGE 30 VOLUME

$504,510

Company detail

CEO: Hing C. Wong
Region: US
Website: hcwbiologics.com
Employees: 40
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

HCW Biologics Inc. focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. Its lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia.

HCWB - HCW Biologics Inc.